Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mei-Xia Chen
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial
The Lancet
Medicine
Related publications
Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial
The Lancet Oncology
Oncology
Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)
BMJ Open
Medicine
Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine
Medicine
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Irinotecan–temozolomide With Temsirolimus or Dinutuximab in Children With Refractory or Relapsed Neuroblastoma (COG ANBL1221): An Open-Label, Randomised, Phase 2 Trial
The Lancet Oncology
Oncology
768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
